Investment Rating - The report recommends a "Buy" rating for the industry, predicting that the industry index will outperform the Shanghai Composite Index by 10% or more in the next six months [22]. Core Insights - Orano's revenue for 2024 reached €5.874 billion, representing a year-on-year growth of 23% from €4.775 billion in 2023 [2]. - The net profit attributable to the parent company increased significantly by 192% to €633 million in 2024, compared to €217 million in 2023 [9]. - The backlog of orders reached €9.069 billion, with 42% coming from outside France, indicating a strong market position [1]. Financial Performance Summary 1) Order Backlog - Total order backlog increased to €35.9 billion by the end of 2024, up from €30.8 billion at the end of 2023, with €1.3 billion attributed to market revaluation and currency effects [1]. 2) Revenue Breakdown - Mining revenue was €1.502 billion, a 13.9% increase year-on-year, driven by rising uranium prices [2]. - Front-end revenue remained stable at €1.307 billion, with positive price effects offsetting lower volume effects [2]. - Back-end revenue surged to €3.027 billion, a 41.8% increase, primarily due to a one-time contract with a Japanese utility [2]. 3) Operating Profit - Operating profit for 2024 was €1.085 billion, an increase of €450 million from 2023 [4]. - The mining segment's operating profit decreased to €122 million, reflecting challenges in Niger [7]. - The front-end segment's operating profit rose to €425 million, while the back-end segment's operating profit increased significantly to €616 million [7]. 4) Adjusted Net Profit - Adjusted net profit attributable to the parent company was €597 million in 2024, up from €22 million in 2023 [8]. 5) Cash Flow and Debt - EBITDA for Orano was €2.067 billion, a substantial increase from €1.228 billion in 2023, with an EBITDA margin rising from 25.7% to 35.2% [10]. - As of December 31, 2024, Orano had €1.3 billion in cash and €780 million in net debt, down from €1.48 billion in 2023 [14]. 6) Future Outlook - For 2025, Orano aims for revenues close to €5 billion, with an EBITDA margin between 23% and 25% and positive net cash flow [18].

Investment Rating - The report assigns a "Buy" rating to the company with a target price of 54.95 RMB, based on a 30x PE valuation for 2025, leading to a target market capitalization of 330 billion RMB [4]. Core Views - The company has been a leader in the insulin market for nearly 20 years, being the first domestic company to industrialize the production of third-generation insulin. It holds a 37% share of the total volume of third-generation insulin in the recent procurement, surpassing Novo Nordisk [1]. - Following the recent procurement renewal, the industry is entering a new cycle with both volume and price increases, indicating a reversal of the company's performance bottom. The gross margin is expected to reach 84% in 2025 [2]. - The company is advancing its international commercialization efforts, with a leading position in the industry. It has received FDA and EMA acceptance for its insulin products, indicating strong potential for revenue growth from overseas markets [3]. Summary by Sections Investment Logic - The company has a strong foothold in the insulin market, being the first to produce third-generation insulin in China. Its products cover long-acting, rapid-acting, and premixed insulin segments [1]. Industry Cycle - The recent procurement renewal has led to a price increase of 5-48% for the company's insulin products, with a significant 34% increase for its core product, glargine insulin. The company secured a procurement volume of 46.86 million units, a 32.6% increase from the last procurement [2]. International Commercialization - The company has established a comprehensive international network and is actively expanding its presence in various global markets. It has successfully registered its products in several countries, enhancing its international sales capabilities [3][24]. Financial Forecast - The company is projected to achieve net profits of 6.41 billion, 11.01 billion, and 15.12 billion RMB from 2024 to 2026, with year-on-year growth rates of 88.6%, 71.7%, and 37.4% respectively [4][6].

Dianthus Therapeutics (DNTH) Conference Summary Company Overview - **Company**: Dianthus Therapeutics - **Lead Program**: DNTH103, an antibody targeting the active form of C1S in the classical pathway of the complement system [3][4] Key Value Inflicting Milestones - **Indications**: Focus on neuromuscular conditions including myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP), and multifocal motor neuropathy (MMN) [3][4] - **Dosing**: DNTH103 aims for a low volume of 300 mg in a 2 ml auto-injector, self-administered every two weeks [4][7] - **Safety Profile**: Potentially reduced risk of infections compared to existing treatments due to preservation of lectin and alternative pathways [4][5] Competitive Landscape - **Competitors**: Sanofi's angimosotimab and Rilipibart are mentioned as competitors in the C1S inhibitor space [12][13] - **Differentiation**: DNTH103 is positioned as a more potent antibody requiring lower doses compared to Rilipibart, which requires 600 mg every week [16][30] Clinical Development - **Phase II Trials**: Initiated for MG and MMN, with CIDP in a pivotal Phase III program [9][10] - **Data Expectations**: Anticipated data from MG Phase II in Q3/Q4 2025, followed by MMN and CIDP data in 2026 [10][46] Efficacy and Safety - **Efficacy Benchmark**: Targeting efficacy similar to Ultomiris and Soliris, with a primary endpoint of safety and secondary efficacy measures [49][50] - **Market Comparison**: Ultomiris reported $6.5 billion in sales, with a 33% growth attributed to MG patients [54] Study Design and Recruitment - **CIDP Study Design**: Open-label followed by randomized placebo-controlled trial, allowing refractory patients [20][21] - **MG Study Design**: Three arms with a focus on safety and efficacy, aiming for 20 patients per cohort [49] Market Dynamics - **Market Evolution**: The CIDP market has evolved rapidly, with increased comfort among physicians in diagnosing CIDP [36] - **Potential Head-to-Head Studies**: Depending on competitor data, Dianthus may consider conducting head-to-head studies against IVIG [41][44] Other Considerations - **Oral Compounds**: Discussion on a competitor's oral C1S inhibitor, with skepticism regarding its efficacy and safety profile [59][62] - **Investor Sentiment**: Positive investor response to the CIDP program, leading to a successful $230 million PIPE financing [18] Conclusion Dianthus Therapeutics is advancing its lead program DNTH103 with a focus on safety, efficacy, and patient convenience in treating neuromuscular conditions. The competitive landscape is evolving, and the company is well-positioned to capitalize on upcoming clinical data and market opportunities.

以下文章来源于天天IPO ，作者岳笑笑 天天IPO . 投资界（PEdaily.cn）旗下，专注IPO动态 杭州另一面。 作者 I 岳笑笑 报道 I 投资界PEdaily 一个超级IPO即将诞生。 投资界-天天IPO获悉，港交所官网显示，微医控股有限公司（简称"微医"）递交港交所上市申请，招银国际为独家保荐人。 在成立微医以前，廖杰远的职业轨迹颇为跳脱：毕业后在林业研究所就职，后来毅然跳出体制；1999年曾与刘庆峰等人参与创立科大 讯飞；200 3年开始在一家通信技术公司担任总经理，参与创办中国绿线，在IT行业闯荡数十年…… 直至后来一次意外经历：由于侄子生病，廖杰远陪着家人在七家医院间折腾了十个月，做了两次手术，最后却发现是误诊。正是这段 经历，这让他下定决心——"如果我这辈子还能做一件事，那就是用自己熟悉的技术，让天下人看病不再那么难。" 说干就干，廖杰远从挂号入手。2010年，他在中国绿线最后一次董事会上宣布转换方向，创办微医的前身"挂号网"，带着团队闯入互 联网医疗行业，提供预约挂号、智能分诊等便捷就医服务。 彼时国内互联网医疗刚刚起步，难以嫁接壁垒森严的医疗体系，许多大厂都被医院拒之门外。廖杰远带领 ...

从全球投资者到产业赋能者。 本文为IPO早知道原创 作者｜Stone Jin 微信公众号｜ipozaozhidao 据IPO早知道消息，在第七届进博会期间，凯辉基金与全球制药巨头赛诺菲（Sanofi）签订合作备忘 录深化医疗领域的创新合作。这一合作项目不仅是双方长期合作关系的进一步深化，更是对推动中法 合作以及中国医药产业转型与升级的积极响应。 此次合作在为中国创新医药提供创新生态圈的支持之外，更结合了赛诺菲在全球制药行业的技术积累 与凯辉基金的行业洞察和跨境投资经验，从研发、临床实验到市场推广、监管合规等多个维度提供全 方位的解决方案，帮助中国医药创新生态发展，实现技术突破和商业化成功，从而释放中国创新的全 球化潜力。 目前，凯辉基金已在全球范围内投资超47家医疗健康相关企业，积极促进全球医疗合作与发展。凯 辉基金创始人及董事长蔡明泼表示："此次合作备忘录的签订不仅是双方在战略上的深度共鸣，更是 共同致力于推动中国医疗健康事业的重要里程碑。 我们期待通过这一合作实现全球领先医药企业与 本土创新力量的双向赋能，并推动更多优秀的中国创新药企实现可持续发展，为患者带来更好的治疗 选择，同时为社会创造更大的价值。" ...

Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 TABLE OF CONTENTS As filed with the United States Securities and Exchange Commission on May 21, 2024 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Perceptive Capital Solutions Corp (Exact name of registrant as specified in its charter) Cayman Islands 6770 98-1783595 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) 51 Astor Pla ...

大的市场风险。投资者应充分了解创业板的投资风险及本公司所披露的风险因素，审慎作出投 资决定。 金凯（辽宁）生命科技股份有限公司 （辽宁省阜新市阜蒙县伊吗图镇氟化工园区安仁路 6 号） 招股说明书 （住所：北京市朝阳区安立路 66 号 4 号楼） 首次公开发行股票并在创业板上市 保荐人（主承销商） 创业板风险提示：本次发行股票拟在创业板上市，创业板公司具有创新投入大、新旧产业融合 存在不确定性、尚处于成长期、经营风险高、业绩不稳定、退市风险高等特点，投资者面临较 金凯（辽宁）生命科技股份有限公司 招股说明书 声明与承诺 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对发行 人注册申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其 对发行人的盈利能力、投资价值或者对投资者的收益作出实质性判断或保证。任 何与之相反的声明均属虚假不实陈述。 根据《证券法》规定，股票依法发行后，发行人经营与收益的变化，由发行 人自行负责；投资者自主判断发行人的投资价值，自主作出投资决策，自行承担 股票依法发行后因发行人经营与收益变化或者股票价格变动引致的投资风险。 | 发行股票类型 | 股） 人民币普通股（ ...